generation run 2026-05-11
89 min completedmodel pipeline-v5plan not recordedrun/d19684dd…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- sparse_evidence
- sparse_evidence
- sparse_evidence
Reproduce
- inputs
- 25 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
16 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | PubMed | tetrahydrocannabiphorol THCP cannabinoid pharmacology | 3 | 3 | All directly relevant; Citti 2019 is the primary discovery paper |
| 2 | PubChem | tetrahydrocannabiphorol | 1 | 1 | Primary compound identity confirmation |
| 3 | PubMed | Citti cannabinoid phytocannabinoid Cannabis sativa isolation | 4 | 2 | Contextual: the cannabidihexol paper directly discusses THCP/CBDP discovery in the same FM2 cannabis variety; enantioseparation paper relevant to THCP stereochemistry |
| 4 | OpenAlex | tetrahydrocannabiphorol THCP | 10 | 4 | Selected papers directly discussing THCP or closely related phytocannabinoid homologs |
| 5 | PubMed | THCP tetrahydrocannabiphorol metabolism toxicology forensic | 2 | 1 | Validated analytical method covering THCP in forensic matrices |
| 6 | OpenAlex | THCP tetrahydrocannabiphorol legal scheduling emerging cannabinoid | 10 | 4 | Directly relevant to THCP's forensic presence, legal status, and regulatory context |
| 7 | ClinicalTrials.gov · absence | tetrahydrocannabiphorol THCP | 0 | 0 | No trials exist |
| 8 | Crossref via verify_doi | 10.3390/psychoactives3040030 | 1 | 1 | Confirmed valid DOI for THCP synthetic impurities paper; important for documenting semi-synthetic nature of commercial THCP |
| 9 | WebSearch | THCP tetrahydrocannabiphorol legal status DEA scheduling United States 2024 2025 | 10 | 3 | Legal status landscape summary; web-retrieved only, needs flag |
| 10 | PubMed | PMID 37269160, 38894658, 38804224 | 3 | 3 | HHCP is the hydrogenated analog of THCP sharing the C7 chain; its pharmacology and metabolism are best available analogs for THCP |
| 11 | WebFetch | — | 1 | 0 | Could not extract usable data from PDF format |
| 12 | WebSearch | THCP tetrahydrocannabiphorol legal status UK Europe Australia scheduling 2024 | 10 | 2 | EU/UK legal landscape web-retrieved summary |
| 13 | PubMed | cannabinoid use disorder cannabis dependence withdrawal clinical | 8 | 1 | Provides dependence/withdrawal framework applicable by class to THCP as CB1 full agonist |
| 14 | WebSearch | THCP tetrahydrocannabiphorol CB2 receptor binding Ki potency compared THC | 10 | 0 | Confirmed receptor binding data already found in Citti 2019 (Ref 1); no new primary source needed |
| 15 | OpenAlex | THCP tetrahydrocannabiphorol drug testing immunoassay forensic toxicology | 7 | 4 | Critical for forensic/analytical section; HHCP metabolite data provides best available analog for THCP metabolite prediction |
| 16 | Multiple sources | THCP data synthesis across all findings | 31 | 6 | Core citation set for research output |
60 claims by section — every cited sentence, checked against its source
safety13 · 11 ok
Claim in safety — inconclusiveinconclusiveworking →
Analysis of a commercial THCP vape cartridge revealed unlabeled synthetic impurities including 5-heptylresorcinol, bisalkylated compounds, and Δ8-THCP isomerssupported
Identified Δ9-THCP, Δ8-THCP, CBP, CBDP, terpenes, plus synthetic impurities including 5-heptylresorcinol and bisalkylated side products consistent with chemical synthesis from olivetol analog. psychoactives3040030
Product declarations may not accurately reflect THCP content.supported
GC-MS analysis of a vape liquid claiming 90% THCP + 10% terpenes. Identified Δ9-THCP, Δ8-THCP, CBP, CBDP, terpenes, plus synthetic impurities... psychoactives3040030
Acute cannabis-associated psychotic symptoms (CAPS) — including hallucinations, paranoia, and disorganized thinking requiring emergency treatment — occur in approximately 0.47% of cannabis users over a lifetime, with substantially elevated risk in young users, users of high-potency preparations, and individuals with pre-existing psychiatric vulnerabilitysupported
0.47% of 233,475 cannabis users reported lifetime CAPS requiring emergency treatment. Young age, high-potency resin, co-use with tobacco, and pre-existing mental health diagnoses (psychosis, bipolar, anxiety, depression) correlated with elevated risk. s41398-022-02112-8
High-potency cannabis is specifically associated with poorer mental health outcomes in adolescents, including increased rates of anxiety disorders, depression, and psychotic experiencessupported
Longitudinal study in adolescents finding association between high-potency cannabis use and poorer mental health outcomes including psychosis. jamapsychiatry.2020.1035
By class mechanism, chronic CB1 agonist exposure produces receptor desensitization (uncoupling from G-proteins) and downregulation (reduced receptor density), resulting in behavioral tolerancesupported
Chronic cannabinoid use downregulates CB1 signaling causing tolerance and dependence. 25-0009
No pharmacotherapy is currently approved for cannabis withdrawal syndromesupported
No pharmacotherapies currently approved for cannabis use disorder. Withdrawal characterized by irritability, sleep disturbance, anxiety, nausea. 02698811251399593
All interaction data are inferred from Δ9-THC class pharmacology.supported
THC primarily metabolized by CYP2C9 and CYP3A4... Cannabinoids are inhibitors of multiple CYPs. 03602532.2013.849268
All interaction data are inferred from Δ9-THC class pharmacology.supported
CYP2C9, CYP3A4, CYP1A2 relevant for THC interactions. Cannabis may affect anticoagulants (warfarin), immunosuppressants, and antiepileptics via CYP inhibition. jcp.0000000000001089
Anesthetic interactions: Chronic cannabinoid use is associated with increased propofol requirements and altered opioid responsiveness during anesthesiasupported
Cannabis users may require higher propofol doses (CYP450 induction + CB1 downregulation). Altered responses to opioids, ketamine, gabapentinoids. 25-0009
Absolute contraindications: * Personal or family history of psychotic disorders (schizophrenia, schizoaffective disorder) — CB1 agonism precipitates and exacerbates psychotic symptoms; full agonism at THCP's potency amplifies this risk * Unstable cardiovascular disease — tachycardia and hemodynamic effects of potent CB1 agonism pose risk in the context of arrhythmia, recent myocardial infarction, or heart failuresupported
Pre-existing mental health diagnoses (psychosis, bipolar, anxiety, depression) correlated with elevated risk. s41398-022-02112-8
Claim in safety — inconclusiveinconclusiveworking →
Relative contraindications: * Bipolar disorder — CB1 agonism may precipitate manic episodes in susceptible individuals * Pregnancy and lactation — cannabinoids cross the placenta and are present in breast milk; high-potency CB1 agonism poses unknown developmental risk * Adolescence — developing endocannabinoid systems are vulnerable to disruption by exogenous high-potency agonists * Concurrent use of CYP2C9 or CYP3A4 substrates with narrow therapeutic indices (warfarin, tacrolimus, cyclosporine) * History of cannabis use disorder — full agonism and higher potency predict elevated reinforcement * Hepatic impairment — reduced CYP metabolism may increase THCP exposure and prolong effectspartially supported
CYP2C9, CYP3A4, CYP1A2 relevant for THC interactions. Cannabis may affect anticoagulants (warfarin), immunosuppressants, and antiepileptics via CYP inhibition. jcp.0000000000001089
pharmacology9 · 6 ok
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Full agonism distinguishes THCP from Δ9-THC, which functions as a partial agonist at CB1 — a difference that may result in greater intrinsic efficacy and a higher ceiling of pharmacological effect.supported
THCP, THCH, THC-C8, HHC, and HHCP identified as having higher CB1 activation potential than Δ9-THC. s00204-024-03769-4
Claim in pharmacology — inconclusiveinconclusiveworking →
The cannabinoid tetrad pharmacological test in mice demonstrated all four classic cannabimimetic effects at doses where Δ9-THC was inactive or less effective:supported
In the cannabinoid tetrad pharmacological test, Δ9-THCP induced hypomotility, analgesia, catalepsy and decreased rectal temperature. s41598-019-56785-1
Metabolism: By analogy with Δ9-THC metabolism (primarily CYP2C9 and CYP3A4) and HHCP metabolism characterized via human hepatocyte incubation, the primary metabolic route is expected to be C-11 hydroxylation (analogous to 11-OH-THC formation), with additional side-chain hydroxylation at the C-5' and C-7' positionssupported
THC primarily metabolized by CYP2C9 and CYP3A4; CBD by CYP2C19 and CYP3A4; CBN by CYP2C9 and CYP3A4. 03602532.2013.849268
Metabolism: By analogy with Δ9-THC metabolism (primarily CYP2C9 and CYP3A4) and HHCP metabolism characterized via human hepatocyte incubation, the primary metabolic route is expected to be C-11 hydroxylation (analogous to 11-OH-THC formation), with additional side-chain hydroxylation at the C-5' and C-7' positionssupported
18 metabolites identified in urine; 11-OH, 5'-OH were present in all samples. Longer alkyl chain of HHCP led to greater side-chain hydroxylation than HHC. dta.3740
Metabolism: By analogy with Δ9-THC metabolism (primarily CYP2C9 and CYP3A4) and HHCP metabolism characterized via human hepatocyte incubation, the primary metabolic route is expected to be C-11 hydroxylation (analogous to 11-OH-THC formation), with additional side-chain hydroxylation at the C-5' and C-7' positionssupported
Monohydroxylated and bishydroxylated metabolites and their glucuronides proposed as forensic targets. dta.3871
In human urine studies of HHCP, 99.3% of hydroxylated metabolites were present as glucuronide conjugates.supported
99.3% of hydroxylated metabolites glucuronidated. dta.3740
summary8 · 6 ok
This structural difference confers a CB1 receptor binding affinity of Ki = 1.2 nM — approximately 33-fold greater than Δ9-THC — making THCP the most potent phytocannabinoid identified at the CB1 receptor to date.partially supported
Its binding activity against human CB1 receptor in vitro (Ki = 1.2 nM) was similar to CP55940 (Ki = 0.9 nM), a potent full CB1 agonist. s41598-019-56785-1
Claim in summary — inconclusiveinconclusiveworking →
The compound entered the recreational cannabinoid market by 2022–2023 as a commercially synthesized product, typically sold in vape cartridges and ediblessupported
GC-MS analysis of a vape liquid claiming 90% THCP + 10% terpenes. Identified Δ9-THCP... plus synthetic impurities... consistent with chemical synthesis from olivetol analog. psychoactives3040030
THCP functions as a full agonist at the CB1 receptor (Ki = 1.2 nM), contrasting with Δ9-THC's partial agonism at the same target (Ki ≈ 10–40 nM)partially supported
Its binding activity against human CB1 receptor in vitro (Ki = 1.2 nM) was similar to CP55940 (Ki = 0.9 nM), a potent full CB1 agonist. s41598-019-56785-1
Claim in summary — inconclusiveinconclusiveworking →
The experiential profile, drawn entirely from consumer self-reports, includes intense sedation, pronounced euphoria, marked cognitive impairment, appetite stimulation, and altered time perception — qualitatively similar to Δ9-THC but reportedly more intense and longer-lasting at lower doses.supported
Comprehensive review of THC-like cannabinoids on the recreational market including chemistry, synthesis, pharmacology, analytical methods, and subjective effects from recreational user reports on online forums. s42238-024-00226-y
Full agonism at CB1 — a pharmacological profile shared with synthetic cannabinoids associated with seizures, psychosis, and loss of consciousness — places THCP in a higher risk category than partial-agonist phytocannabinoids like THCsupported
Potency dramatically higher than THC; intoxication, withdrawal, psychosis, death reported. Emphasizes dangers of high-potency full CB1 agonists with unknown pharmacology. fnbeh.2011.00060
Tolerance develops through CB1 receptor desensitization and downregulation; cross-tolerance with Δ9-THC is expected but not experimentally confirmedsupported
Chronic cannabinoid use downregulates CB1 signaling causing tolerance and dependence. 25-0009
history7 · 4 ok
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
The same research group subsequently expanded the phytocannabinoid homolog series, identifying cannabidihexol (CBDH) and Δ9-tetrahydrocannabihexol (Δ9-THCH, a C6-chain homolog) in 2020supported
New phytocannabinoids CBDH and Δ9-THCH isolated from FM2 medicinal cannabis variety. Paper explicitly mentions THCP and CBDP as previously discovered by same group. s41598-020-79042-2
Claim in history — inconclusiveinconclusiveworking →
By 2022–2023, THCP-containing vape cartridges and edibles were commercially available in Europe and North Americasupported
Comprehensive review of THC-like cannabinoids on the recreational market including chemistry, synthesis, pharmacology, analytical methods, and subjective effects from recreational user reports. s42238-024-00226-y
In Sweden, THCP appeared after hexahydrocannabinol (HHC) and HHC-P were classified as narcotics in July 2023, functioning as an unregulated replacementsupported
THC-P (THCP) and HHC-O appeared on Swedish market after HHC/HHC-P were classified as narcotics on 11 July 2023. 00365513.2024.2340039
In Denmark, seized drug analysis identified THCP in approximately 1% of semi-synthetic cannabinoid seizures between 2018 and 2023supported
SSCs in seized cannabis products analyzed over 6 years in Denmark. THCP found at 1% prevalence. 1556-4029.15631
pharmacokinetic-detail7 · 7 ok
Identification of HHCP metabolites in human urine confirmed that mono-hydroxylated species and their glucuronide conjugates are the dominant urinary analytes, with 99.3% of hydroxylated metabolites excreted as glucuronidessupported
99.3% of hydroxylated metabolites glucuronidated. 18 metabolites identified in urine; 11-OH, 5'-OH were present in all samples. dta.3740
HHCP metabolism in human hepatocyte incubations demonstrated monohydroxylation at multiple positions along the C7 chain, followed by oxidation to carboxylic acid metabolites and extensive glucuronidationsupported
HHC and HHCP (heptyl homolog) incubated with primary human hepatocytes. Primary metabolism via monohydroxylation then carboxylic acid. 99.3% of hydroxylated metabolites glucuronidated. dta.3740
HHCP metabolism in human hepatocyte incubations demonstrated monohydroxylation at multiple positions along the C7 chain, followed by oxidation to carboxylic acid metabolites and extensive glucuronidationpartially supported
Human urinary metabolites of HHCP identified after oral consumption. Monohydroxylated and bishydroxylated metabolites and their glucuronides proposed as forensic targets. dta.3871
Standard cannabinoid immunoassays designed to detect THC-COOH (11-nor-9-carboxy-THC) show reduced cross-reactivity with longer-chain cannabinoid metabolitessupported
Longer alkyl side chains result in decreased cross-reactivity relative to Δ9-THC. bkae036
Definitive identification of THCP in biological matrices requires mass spectrometry (LC-MS/MS or LC-QTOF-MS).supported
Validated LC-MS-MS method for quantitative confirmation of Δ8/Δ9-THC and metabolites, and qualitative identification of THCP... in blood and urine. bkaf023
Definitive identification of THCP in biological matrices requires mass spectrometry (LC-MS/MS or LC-QTOF-MS).supported
Validated LC-QTOF-MS screening method for 24 phytocannabinoids and semi-synthetic cannabinoids in blood including THCP. bkaf095
If THCP is metabolized by CYP2C9 and CYP3A4 as inferred from THC pharmacology, it may be subject to pharmacokinetic interactions with inhibitors and inducers of these enzymessupported
THC primarily metabolized by CYP2C9 and CYP3A4... Cannabinoids are inhibitors of multiple CYPs. 03602532.2013.849268
chemistry4 · 3 ok
This two-methylene extension is the sole structural distinction between THCP and THC and is responsible for THCP's dramatically enhanced CB1 receptor affinity.supported
A new phytocannabinoid with the same structure of Δ9-THC but with a seven-term alkyl side chain... Its binding activity against human CB1 receptor in vitro (Ki = 1.2 nM) was similar to CP55940. s41598-019-56785-1
Claim in chemistry — inconclusiveinconclusiveworking →
Chiral analysis of the FM2 medicinal cannabis variety found no (+) enantiomers for any phytocannabinoids examined, consistent with exclusive (-)-trans configuration in planta.supported
FM2 cannabis variety showed no (+) enantiomers, suggesting extraction does not cause configuration inversion. j.jchromb.2023.123682
Commercial THCP products may contain Δ8-THCP isomers (differing in double-bond position) as synthesis byproductssupported
Identified Δ9-THCP, Δ8-THCP, CBP, CBDP, terpenes, plus synthetic impurities... consistent with chemical synthesis from olivetol analog. psychoactives3040030
comparative-pharmacology4 · 2 ok
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
HHCP metabolism data — the most directly applicable analog for predicting THCP metabolism — confirm that the heptyl chain introduces additional hydroxylation sites and results in more complex metabolite profiles.supported
Longer alkyl chain of HHCP led to greater side-chain hydroxylation than HHC. dta.3740
HHCP metabolism data — the most directly applicable analog for predicting THCP metabolism — confirm that the heptyl chain introduces additional hydroxylation sites and results in more complex metabolite profiles.supported
Monohydroxylated and bishydroxylated metabolites and their glucuronides proposed as forensic targets. dta.3871
receptor-pharmacology4 · 2 ok
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
EC50 values at CB1 from the β-arrestin2 recruitment assay are reported in supplementary data by Janssens et al. but were not available in the published abstract.supported
THCP, THCH, THC-C8, HHC, and HHCP identified as having higher CB1 activation potential than Δ9-THC. s00204-024-03769-4
In a panel of 30 THC isomers, homologs, and analogs assessed by β-arrestin2 recruitment bioassay at human CB1, THCP was identified among several compounds (alongside THCH and THC-C8) showing higher CB1 activation potential than Δ9-THC, based on either greater efficacy (Emax) or greater potency (EC50)supported
Panel of 30 THC isomers/homologs/analogs assessed via CB1 beta-arrestin2 recruitment bioassay. THCP, THCH, THC-C8, HHC, and HHCP identified as having higher CB1 activation potential than Δ9-THC. s00204-024-03769-4
neuroscience2 · 2 ok
THCP's dose-dependent transition from anxiolysis to anxiogenesis, as described in consumer reports, is consistent with this bidirectional mechanism.supported
Comprehensive review of THC-like cannabinoids on the recreational market including... subjective effects from recreational user reports on online forums. Covers THCP and related homologs. s42238-024-00226-y
CB1 receptor downregulation and desensitization represent the system's attempt to restore homeostasis in the face of persistent exogenous agonism.supported
Chronic cannabinoid use downregulates CB1 signaling causing tolerance and dependence. 25-0009
effects-overview1 · 1 ok
The experiential consequence, based on consumer reports, is a cannabinoid state that can escalate beyond the bounds of typical cannabis experience into territory more commonly associated with high-potency synthetic cannabinoids.supported
Comprehensive review of THC-like cannabinoids on the recreational market including chemistry, synthesis, pharmacology, analytical methods, and subjective effects from recreational user reports on online forums. s42238-024-00226-y
legal-status1 · 1 ok
The scheduling trajectory across jurisdictions follows a consistent pattern: THCP enters markets as an unregulated alternative after related compounds (HHC, HHC-P, THC-O) are scheduled, prompting reactive regulatory responses within 12–24 monthssupported
THC-P (THCP) and HHC-O appeared on Swedish market after HHC/HHC-P were classified as narcotics on 11 July 2023. 00365513.2024.2340039